Help advance science and get compensated! GWU needs teen vaccine participants.
Area teens ages 12 to 17 are welcome to enroll in a clinical trial to study the mpox vaccine (formerly known as monkeypox) in adolescents. This NIH-led mpox trial is recruiting at the George Washington University Vaccine Research Unit (VRU) as well as at 17 other sites across the country.
The researchers are attempting to gain FDA approval for the JYNNEOS vaccine in adolescents to prevent future outbreaks, such as the one that alarmed the world last year. Currently, the JYNNEOS vaccine is only approved for adults.
Parents are encouraged to enroll in the trial with their child. Participants will be compensated.
“We are excited to have launched the next stage of this clinical trial, which can help determine if this vaccine can be used to protect adolescents should there be another large outbreak in the United States or some other part of the world,” said David Diemert, clinical director of GWU’s Vaccine Research Unit. “Having a safe and effective vaccine at the ready would help prepare the United States and other countries for the next outbreak of this disease.”
Mpox is a rare zoonotic disease, with flu-like symptoms including rash, fever, headache, chills, and other ailments; the disease can be serious in many people, especially young children, adolescents, and those with weakened immune systems.
Study visits are conducted at the GW Medical Faculty Associates offices in Foggy Bottom, convenient to the Foggy Bottom Metro Station and several bus lines.
Sign up here to enroll in the study. More information about the study is at this media announcement.
